[Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine].
OBJECTIVE
To establish gemcitabine-resistant pancreatic cancer cell strain and study the role of thioredoxin reductase (TrxR) in drug-resistant process.


METHODS
Gemcitabine-resistant pancreatic cancer cell strain SW1990/GZ was induced by increasing drug dosage intermittently, then the changes of its biological features and the activity of TrxR were examined.


RESULTS
Stable drug-resistant SW1990/GZ cell strain was established by culturing with gemcitabine for 9 months. The morphology and growth characteristics of the cell strain changed remarkably. The cells shrunk and became rounder; its endoplasm expanded; granular substances increased; and the doubling-time was prolonged. Resistance of the cell line to gemcitabine, fluorouracil, adriamycin, and mitomycin significantly increased. The TrxR activity of the drug-resistant cells was increased markedly.


CONCLUSIONS
SW1990/GZ has certain multidrug resistance to some chemotherapy drugs, and TrxR plays a role in the drug-resistant process.
Niu
Bei-zhan
BZ
Department of General Surgery, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
Chen
Ge
G
Li
Li-jun
LJ
Wu
Yuan-de
YD
Zhao
Yu-Pei
YP
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D013880:Thioredoxin-Disulfide Reductase / Q000187:drug effects / Q000378:metabolism*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D013880:Thioredoxin-Disulfide Reductase; D000093542:Gemcitabine